Announcement on Abnormal Fluctuations in Stock Trading
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
Lionco Pharmaceutical Group Co., Ltd. has issued an announcement regarding abnormal fluctuations in its stock trading. The company's stock experienced significant price declines over three consecutive trading days, which qualifies as abnormal trading activity according to exchange rules. The company confirmed that its production and operational status remains normal and that there are no undisclosed significant matters affecting stock prices. Investors are advised to be cautious and make informed decisions due to the trading risks associated with these fluctuations.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Lionco Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Lionco Pharmaceutical
- Semi-annual Performance Forecast for 2026
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on Follow-up Rating Results of "Lionco Convertible Bonds" in 2026
- Announcement on No Downward Revision of Conversion Price of "Lionco Convertible Bonds"
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
Later from Lionco Pharmaceutical
- Indicative Announcement on "Lionco Convertible Bonds" Expected to Meet Conditions for Revising Conversion Price
- Announcement on Selection of the Subsidiary's Product Huperzine A for Injection in the Inter-Provincial Alliance Centralized Procurement
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- Announcement on Resolutions of the 12th Meeting of the 5th Board of Directors
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
Follow Lionco Pharmaceutical into a list and get an email when it puts out news.
Follow Lionco Pharmaceutical